ASCO sets the scientific direction for oncology drug development each year, but translating those insights into executable trial strategy remains one of the most persistent challenges sponsors face. As protocols grow more complex and timelines compress, delays are increasingly driven by how programs are operationalized, not by the science itself. In this Post-ASCO Insights Webinar, oncology leaders from Worldwide Clinical Trials, Adcentrx Therapeutics, Kumquat Bioscience, and START Madrid‑FJD explore how the most relevant themes from ASCO 2026 translate beyond the data, connecting emerging scientific directions to the practical realities of planning and running oncology trials across global studies.
Watch the replay to gain a clearer understanding of how to turn ASCO insights into actionable execution choices, including:
- How emerging modalities, biomarker-driven approaches, and the growing role of AI are shaping trial design decisions and what that means for operational planning
- Strategies for managing protocol and cohort complexity as oncology programs scale in scope and scientific ambition
- How to align clinical and operational teams around decision-critical endpoints to maintain rigor without sacrificing speed
- Practical approaches to navigating oversight, safety review, vendor management, logistics, and data flows across global studies
- How site strategy and activation fit within a broader execution framework — and why treating them in isolation can slow program momentum
